When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @RheumNow @ElaineHusniMD

“We are giving autoimmune diseases to ourselves through bad diet.” — Dr. Gregg Silverman, #ACR20 @RheumNow @drnatalietv

@RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/sQK4L7Zu76

“Avacopan is the little train that could that will eat the antibodies lunch!” - Dr. Gregg Silverman #ACR20 @RheumNow @petermerkel @LCalabreseDO @philseo @AdamJBrownMD

As #ACR20 is wrapping up, are you are planning to see the conference lectures after the meeting is over? @RheumNow

Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH

@rheumnow #ACR20 abs1535 retrospective study of SI MRI reveals 20% pts w/out spondyloarthritis have BME on an MRI, predominantly in the antero-middle quadrant. Erosions were seen in 31% of healthy patients and in 61% of patients with spondyloarthritis

Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

“Rheumatologists diagnose diseases of inflammation, and we are really good at it!” - Dr. Greg Silverman #ACR20 @RheumNow

About half (51%) of patients from the FORWARD registry in the US had at least one telehealth appointment during COVID-19 pandemic and most were satisfied with the appointment @RheumNow #ACR20 Abstr#1962 https://t.co/z38ilD1n8Q

Summary of #ACR20 part A: - HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation - Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS @rheumnow

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by @RheumNow & its Faculty.